Aurobindo Pharma Limited — Others, 30-04-2025: Action(s) taken or orders passed

Aurobindo Pharma has faced a setback with the appellate authority rejecting its appeal concerning a GST demand from the financial year 2019-20. The order mandates a reversal of Input Tax Credit (ITC) of ₹3.74 Cr, alongside additional interest of ₹2.94 Cr and a penalty of ₹0.38 Cr, culminating in a total dispute of ₹7.06 Cr. The company intends to appeal to the Appellate Tribunal (GSTAT), but it emphasizes that this ruling is not expected to significantly affect its financial performance or operations.